Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy

Anjali S. Advani, MD, Holly Gundacker, Nolyn Nyatanga, MD, Paul Elson, Peter J. Rosen, MD, Jennifer Bates, BS, CCRP, Mikkael A. Sekeres, MD, MS, Matt Kalaycio, MD, Ronald Sobecks, MD, Edward Copelan, MD, Frederick R. Appelbaum, MD

Blood (2011) 118 (21): 2594.

https://doi.org/10.1182/blood.V118.21.2594.2594

Published: 2011

Journal Articles

Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia

Di Sun, Paul Elson, Michaela Liedtke, MD, Bruno C. Medeiros, MD, Marc Earl, PharmD, RPh, Ash A Alizadeh, MD/PhD, Jennifer Bates, BS, CCRP, Mikkael A. Sekeres, MD, MS, Steven E. Coutre, MD, Matt Kalaycio, MD, Ronald Sobecks, MD, Edward Copelan, MD, Anjali S. Advani, MD

Blood (2011) 118 (21): 2552.

https://doi.org/10.1182/blood.V118.21.2552.2552

Published: 2011

Journal Articles

Lenalidomide and Rituximab Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin Lymphoma Is Associated with Unacceptable Myelotoxicity

Robert Dean, MD, Brad Pohlman, MD, Lisa Rybicki, MS, Amanda L. Maggiotto, BS, CCRP, Jennifer Bates, BS, CCRP, Stephen D. Smith, MD, Brian J. Bolwell, MD, John Sweetenham, MD

Blood (2011) 118 (21): 1621.

https://doi.org/10.1182/blood.V118.21.1621.1621

Published: 2011

Journal Articles

Comparison of T Cell (CD3+) Chimerism after Myeloablative (MY) and Nonmyeloablative (NM) Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).

Ronald Sobecks, MD, Karl Theil, MD, Lisa Rybicki, MS, Jennifer Bates, BS, Matt Kalaycio, MD, Steven Andresen, DO, Brad Pohlman, MD, Robert M. Dean, MD, John William Sweetenham, MD, Laura Bernhard, RN, Kelly Cherni, RN, Mary Serafin, RN, Karen Sands, RN, Jennifer Kosar, RN, Brian J. Bolwell, MD

Blood (2006) 108 (11): 2960.

https://doi.org/10.1182/blood.V108.11.2960.2960

Published: 2006

Journal Articles

Influence of Killer Immunoglobulin-Like Receptor (KIR) Matching on Achieving T Cell (CD3+) Complete Donor Chimerism (CDC) in Related Donor Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHSCT).

Ronald Sobecks, MD, Edward J. Ball, PhD, Medhat Askar, MD, PhD., Karl Theil, MD, Lisa Rybicki, MS, Dawn Thomas, CHS, Jennifer Bates, BS, Matt Kalaycio, MD, Steven Andresen, DO, Brad Pohlman, MD, Robert M. Dean, MD, John William Sweetenham, MD, Laura Bernhard, RN, Kelly Cherni, RN, Jaroslaw P. Maciejewski, MD, MS, Brian J. Bolwell, MD

Blood (2006) 108 (11): 3012.

https://doi.org/10.1182/blood.V108.11.3012.3012

Published: 2006

NARROW

Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy

Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia

Lenalidomide and Rituximab Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin Lymphoma Is Associated with Unacceptable Myelotoxicity

Comparison of T Cell (CD3+) Chimerism after Myeloablative (MY) and Nonmyeloablative (NM) Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).

Influence of Killer Immunoglobulin-Like Receptor (KIR) Matching on Achieving T Cell (CD3+) Complete Donor Chimerism (CDC) in Related Donor Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHSCT).

Email alerts

ASH Publications

American Society of Hematology

Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy

Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia

Lenalidomide and Rituximab Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin Lymphoma Is Associated with Unacceptable Myelotoxicity

Comparison of T Cell (CD3+) Chimerism after Myeloablative (MY) and Nonmyeloablative (NM) Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).

Influence of Killer Immunoglobulin-Like Receptor (KIR) Matching on Achieving T Cell (CD3+) Complete Donor Chimerism (CDC) in Related Donor Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHSCT).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only